forum
IPCALAB Share Price Target
Ipca Laboratories Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
IPCALAB Share Price *
955 +11.95 (1.27%)
* (quote may be delayed)
IPCALAB Share Price Forecast - Consensus
| No. of reports in last year | 11 |
| No. of analysts | 6 |
| Average Consensus Forecast | 988.55 |
| Consensus Potential | 3.47% |
IPCALAB Share Price Target - Broker Reports - 2019
YES Securities
19-Aug-19
Price @ Call: 939.5
Target: 1100
BUY
Domestic business guidance of 13-15% is ahead of prior indication while API growth has surprised on the upside. This leads to a cut in margin due to rise in API share even as the reduction is cushioned by larger base of absolute EBIDTA. We like the revenue visibility coupled with lack of margin volatility due to absence of US business. Retain BUY based on 21x FY21 PE, at a premium to the sector valuation with unchanged 1-year PT of Rs1,100.
Prabhudas Lilladher
14-Aug-19
Price @ Call: 939.53
Target: 1008
ACCUMULATE
ACCUMULATE | CMP: Rs940 | TP: Rs1,008
EBITDA margin is guided to improve by 100-200bps in FY20E due to the benefits operating leverage. We expect slower offtake of Global Fund business may shift some of its sales to FY21E. IPCA trades at PER of 22x (FY20E) and 18.3x (FY21E). With better visibility of exports, we increase our TP to Rs1,008 (from Rs908) on PE 20xof FY21 earnings while downgrade ourratings to ‘Accumulate’ as upside potential at current valuation is 8%.
EBITDA margin is guided to improve by 100-200bps in FY20E due to the benefits operating leverage. We expect slower offtake of Global Fund business may shift some of its sales to FY21E. IPCA trades at PER of 22x (FY20E) and 18.3x (FY21E). With better visibility of exports, we increase our TP to Rs1,008 (from Rs908) on PE 20xof FY21 earnings while downgrade ourratings to ‘Accumulate’ as upside potential at current valuation is 8%.
ICICIdirect.com
31-May-19
Price @ Call: 941.65
Target: 1130
BUY
The company has demonstrated significant improvement in the financials in FY19 with ~15% sales growth, 450 bps improvement in EBITDA margins and more importantly 630 bps improvement in ROCE. This, we believe was attributable to industry beating growth in the domestic formulations and strong growth in APIs. Going ahead, with firm growth tempo in the domestic formulations and good prospects both for API exports and formulation exports we expect further improvement in the financial parameters. The company will continue to remain a compelling bet on the back of well- rounded growth prospects for FY19–21E- sales, EBITDA and PAT CAGR of 14%, 22% and 27%, respectively. We arrive at our target price of Rs 1130 (20x FY21E EPS of | 56.4).
Karvy Stock Broking
31-May-19
Price @ Call: 941.65
Target: 1090
BUY
We reduce our Revenues by 3.4%/2.7% for FY20E/FY21E due to downgrade in Generics and Branded business. We upgrade our EBITDAM for FY20E/FY21E by 180 bps for both the years to 21.6 % /22.4 %respectively. We upgrade our EPS estimates by 8.2% /6.2% to Rs 46.9/Rs 58.3 for FY 20E/FY21E. We maintain our BUY rating and price target of Rs 1090 based on 18.6x FY21E.
Motilal Oswal
23-Apr-19
Price @ Call: 960.1
Target: 1145
BUY
Prabhudas Lilladher
7-Mar-19
Price @ Call: 870
Target: 921
BUY
Prabhudas Lilladher
14-Feb-19
Price @ Call: 757.5
Target: 921
BUY
Motilal Oswal
14-Feb-19
Price @ Call: 757.5
Target: 970
BUY
ICICIdirect.com
13-Feb-19
Price @ Call: 752.99
Target: 900
BUY
IPCALAB Share Price Target - Broker Reports - 2018
Prabhudas Lilladher
15-Nov-18
Price @ Call: 742.1
Target: 829
BUY
Rudra Shares & Stocks Brokers
28-Sep-18
Price @ Call: 685.16
Target: 860
BUY
Motilal Oswal
13-Aug-18
Price @ Call: 737.15
Target: 850
BUY
ICICIdirect.com
13-Aug-18
Price @ Call: 736.5
Target: 845
BUY
Motilal Oswal
11-Jul-18
Price @ Call: 710
Target: 825
BUY
Prabhudas Lilladher
31-May-18
Price @ Call: 675.05
Target: 837
BUY
Motilal Oswal
31-May-18
Price @ Call: 672.35
Target: 785
BUY
Edelweiss
31-May-18
Price @ Call: 672.35
Target: 750
BUY
Prabhudas Lilladher
9-Mar-18
Price @ Call: 667.9
Target: 837
BUY
Edelweiss
15-Feb-18
Price @ Call: 639.55
Target: 750
BUY
Motilal Oswal
9-Feb-18
Price @ Call: 589
Target: 750
BUY
IPCALAB Share Price Target - Broker Reports - 2017
Angel Broking
28-Nov-17
Price @ Call: 541.8
Target: 570
ACCUMULATE
Edelweiss
16-Nov-17
Price @ Call: 526.35
Target: 440
SELL
Motilal Oswal
15-Nov-17
Price @ Call: 535.9
Target: 550
NEUTRAL
Indiabulls Ventures
26-Oct-17
Price @ Call: 500.17
Target: 660
BUY
ICICIdirect.com
31-May-17
Price @ Call: 490
Target: 525
HOLD
Axis Direct
16-Feb-17
Price @ Call: 519
Target: 580
BUY
Khambatta Securities
14-Feb-17
Price @ Call: 521
Target: 556
HOLD
ICICIdirect.com
13-Feb-17
Price @ Call: 518
Target: 560
HOLD
IPCALAB Share Price Target - Broker Reports - 2016
ICICIdirect.com
16-Nov-16
Price @ Call: 540
Target: 605
BUY
Khambatta Securities
16-Nov-16
Price @ Call: 525
Target: 557
BUY
Angel Broking
16-Nov-16
Price @ Call: 540
Target: 613
BUY
Edelweiss
15-Nov-16
Price @ Call: 541
Target: 420
REDUCE
Khambatta Securities
19-Aug-16
Price @ Call: 511
Target: 595
BUY
India Nivesh
17-Aug-16
Price @ Call: 520.45
Target: 611
BUY
Khambatta Securities
3-Jun-16
Price @ Call: 418
Target: 470
BUY
ICICIdirect.com
1-Jun-16
Price @ Call: 430
Target: 455
HOLD
Edelweiss
7-Apr-16
Price @ Call: 558
Target: 440
REDUCE